Juno Therapeutics CEO gives 2017 outlook after drug trial halt cut stock in half last year | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 9 January, 2017 by The TZ Newswire Staff

Juno Therapeutics CEO gives 2017 outlook after drug trial halt cut stock in half last year

Hans Bishop gives an update on Juno Therapeutics in an exclusive interview with CNBC’s Meg Tirrell.

See also
- Next Article The two kinds of US dollar rallies – Morgan Stanley
- Previous Article Op-Ed: Sorry, Donald Trump. A ‘terrific’ replacement for Obamacare just doesn’t exist
Editorial Calender

January 2017

M T W T F S S

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30 31

« Dec Feb »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar